Hematologic Oncology

It was midnight and I had just been jarred out of a sound sleep by the startlingly repetitive beeping of my pager.

Extracorporeal photopheresis takes approximately 3 to 4 hours to complete and involves leukapheresis, separation of the buffy coat, photoactivation, and finally reinfusion.

Dr. Sonali Smith director Lymphoma Program at the University of Chicago Medical Center Discusses Lymphoma in the Elderly

FDA digest from June discussing warning labels, pancreatic treatment choices, and the quest for a lymphoma drug.

Tips for success from Lawrence B. Afrin, MD an associate professor of medicine in the Division of Hematology/Oncology at Medical University of South Carolina in Charleston.

The FDA has granted accelerated approval for Istodax (romidepsin) to be used as treatment for an aggressive form of non-Hodgkin lymphoma

Dr Kris From Memorial Sloan-Kettering Cancer Center Discusses Methotrexate in Acute Lymphocytic Leukemia

Hematologic cancer resources gathered from across the web including a news brief, patient education, clinical trials and CME/CE

Amonafide+Cytarabine may not be effective for secondary acute myeloid leukemia, according to ACCEDE trial data

High doses of methotrexate increases EFS for children and young adults

Researchers at North Carolina State University used canines as genetic models for studying lymphomas

Reynaldo Garcia from the UNC Lineberger Comprehensive Cancer Center Explains the BCR-ABL Study

Reynaldo Garcia from the University of North Carolina Lineberger Comprehensive Cancer Center on BCR-ABL Testing in Chronic Myelogenous Leukemia

Oncologist James Berenson, MD, likes all of his patients, especially the ones with whom he skis.

Revlimid (lenalidomide) has demonstrated dramatic, long-term benefits as a second-line therapy for patients with multiple myeloma

Researchers have sequenced 38 tumor genomes from patients with multiple myeloma (MM), comparing them with normal DNA.

Seattle Genetics, Inc announced on Monday that the FDA has accepted filings for two Biologics License Applications for bretuximab vedotin

The American Society of Hematology (ASH) is sounding a fresh alarm about ongoing supply problems with oncology drugs

The FDA reported today that TNF blockers may be responsible for an increased incidence of HSTCL in adolescents and young adults

The brave, (relatively) new world of social networking has presented even the medical community with challenges, but with a few precautions fellows can avoid some of the pitfalls associated with an online presence.

Genome sequencing may help researchers understand the pathogenesis of this cancer, which despite exhaustive research, is only partially understood

A new tool for mapping disease severity and outcomes in patients with Gaucher disease (GD) may help physicians develop a standardized approach to treatment

Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, discusses front-line treatments for CML, at the 2010 ASCO Annual Meeting.

Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, on second-generation TKIs for patients with CML, a cancer that starts inside bone marrow.

Rituximab is a humanized monoclonal antibody that is used for the treatment of a wide variety of B-cell-derived hematologic malignancies